CA2347032A1 - O/w emulsion comprising an hydroxylated oil - Google Patents
O/w emulsion comprising an hydroxylated oil Download PDFInfo
- Publication number
- CA2347032A1 CA2347032A1 CA002347032A CA2347032A CA2347032A1 CA 2347032 A1 CA2347032 A1 CA 2347032A1 CA 002347032 A CA002347032 A CA 002347032A CA 2347032 A CA2347032 A CA 2347032A CA 2347032 A1 CA2347032 A1 CA 2347032A1
- Authority
- CA
- Canada
- Prior art keywords
- oil
- drug
- emulsion
- composition according
- hydroxylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The present invention provides a composition comprising an oil-in-water emulsion and a drug dissolved in the emulsion. The oil phase comprises a hydroxylated oil, particularly a hydroxylated vegetable oil. The preferred hydroxylated vegetable oil is castor oil.
Description
0/W EMULSION COMPRISING AN HYDROXYLATED OIl.
The present invention relates generally to a new composition for delivery of drugs to the nose far systemic absorption. More specifically, the s present invention relates to an oil-in-water emulsion formulation for the delivery of poorly water soluble drugs, which need to be given in relatively high doses, to the nose for systemic absorption.
Examples of poorly water soluble drugs that are given in relatively high io doses are analgesics, including aon-steroidal anti-inflammatory drugs (NSAIDs), and anti-Parkinson drugs. By a relatively high dose of drug, we mean more than 1 mg of drug.
The nasal route of drug delivery affords rapid absorption of drugs into the is blood circulation. In some cases the absorption of almost the whole dose can be achieved and the pharmacokinetics can be similar to intravenous administration. Such rapid and effective drug delivery can be useful in the treatment of crisis situations such as pain (to include breakthrough pain, headache), migraine, convulsions, impotence and nausea. Nasal 2o formulations for the delivery of analgesic agents such as morphine, butorphanol, fentanyl, buprenorphine have been described. For a review, see Nasal Systemic Delivery, Eds. Chien et al. Dekker, New York, 2s The non-steroidal anti-inflammatory drugs (NSAIDs) such as the cyclooxygenase (COX) COX-1 and COX-2 inhibitors have an important role in pain management. Compounds include ibuprofen, flurbiprofen, diclofenac, indomethacin, piroxicam, ketoprofen, etodolac, diflusinal, meloxicam, aceclofenac, fenoprofen, naproxen, tiaprofenic acid and 3o tolmetin. Such drugs are normally given by mouth for absorption from i the gastrointestinal tract, but can also be given by other routes, which include injection.
Nasal delivery of poorly water soluble drugs that need to be given in a s relatively high dose is often problematic. The maximum volume to be given in each nostril is 100 to 125 ~.1 and with a low solubility of the drug, it is normally not possible to achieve a simple solution formulation.
Moreover, the compounds can be irritant to mucosae.
io It is known that solutions of non-steroidal anti-inflammatory drugs at relatively high concentrations can be prepared by the use of certain salt forms, e.g. K+, or by adjustment of pH. However, the osmolarity of such solutions can readily exceed isotonicity and, as a consequence, the solutions can be irritant.
~s WO-97/03659 describes the use of non-steroidal anti-inflammatory drugs (e.g. diclofenac or ibuprofen) for the treatment of nasal polyps, chronic rhinosinusitis or anosmia. There is no suggestion that the nasal route can be used for the systemic delivery of NSAIDs, nor is there a description of 2o a two phase system, such as an emulsion, for this purpose.
EP-A-0524,587 describes the nasal administration of Ketoroiac (US-4,0$9,969) for analgesic and anti-inflammatory activity. Formulations based on the concepts of bioadhesion, e.g. using cellulose gums and block 2s copolymers, as well as formulations containing enhancing agents are described. The use of an emulsion formulation was not described.
US-5,707,644 describes the nasal delivery of NSAIDs and analgesics to the systemic circulation using small bioadhesive microspheres. There is no suggestion that a two phase liquid formulation, such as an emulsion, could be used.
Oil-in-water emulsion systems for the improved delivery of drugs via the s nasal route have been described previously. Ko et al. (J. Microencaps.
15, 197, 1998) administered testosterone to rabbits. The drug was dissolved in soybean oil. Karali et al. (Pharm. Res. 9, 1024, 1992) used an oleic acid mono-olefin emulsion to deliver a lipid soluble resin inhibitor. The emulsion was effective because it contained membrane io modifying adjuvants. The use of a hydroxylated oil such as castor oil was not disclosed.
WO-93/12764 and GB-2,133,691 describe the potential use of emulsion systems for the nasal delivery of nicotine. The teaching of these two ~s patents is to use systems of a defined viscosity and an oily emulsion is mentioned simply as a formulation option.
JP-4-173736 describes amphotericin containing emulsions and lyophilised counterparts based on soybean oil as the oily phase for use as nasal drops.
2o It is well known that in such emulsions the drug is intercalated into the surface layer of the emulsion and is not dissolved in the oily phase (Davis et al. Ann N.Y. Acad. Sci. 507, 75, 1987).
JP-5-124965 describes the local treatment of nasal disorders using drugs 2s dissolved in the oily phase of an emulsion. The oil phase was soybean oil and the drugs were steroid and steroid derivatives.
JP-7-258069 describes sustained release nasal drops containing vasoconstrictor and antihistamines in an oil-in-water emulsion for local 30 effect.
Emulsion vehicles have also been used to improve the nasal delivery of polar drugs such as peptides and as vaccine adjuvants. In such formulations, the drug is not dissolved in the oil phase of the emulsion, but can be adsorbed to the surface of the emulsion droplets (WO-s 95/11700, US-5,514,670, WO-93/05805, US-5,716,637).
US-5,179,079 describes the use of emulsions to disperse absorption promoting agents such as phospholipids.
io In none of these prior art documents have oil-in-water emulsions based on hydroxylated oils, such as castor oil, been used for the nasal administration of drugs in order to provide for solubilisation of the therapeutic agent and reduced nasal irritation.
is The present applicant has developed an oil-in-water formulation that can provide for the effective nasal delivery of drugs which are poorly soluble in water, such as analgesics, including NSAIDs, and drugs for the treatment of Parkinson's disease and impotence. The composition may also demonstrate a reduced nasal irritation.
According to the present invention, there is provided a pharmaceutical composition comprising (i) an oil-in-water emulsion and (ii) a drug other than a cannabinoid dissolved in the emulsion, wherein the oil phase comprises a hydroxylated oil, particularly a hydroxylated vegetable oil.
The composition of the invention can provide for the delivery of poorly water soluble drugs, which are given in a relatively high dose, to the nasal mucosa for subsequent delivery to the systemic circulation. By a poorly water soluble drug we mean a drug with a solubility in water less than 10 mg/ml at pH 7.4 at 25°C. By _a relatively high dose of drug we mean more than 1 mg of drug.
The drug, which in a preferred embodiment is a poorly water soluble s drug, is preferably largely contained within the oil phase of the oil-in-water emulsion. By "largely" we mean that more than one half, i.e.
more than SO % , and preferably more than 75 % of the available drug is dissolved in the oil phase on a weight basis.
io The hydroxylated oil which is contained in the composition of the invention provides for solubilisation of the drug and can provide for effective solubilisation of poorly water soluble drugs so that a therapeutically relevant dose can be delivered via the nose. Moreover, the emulsion formulation can greatly reduce any irritation associated with the is drug. Without wishing to be bound by any theory, it is believed that such reduction in irritation is due to the fact that the drug is dissolved largely in the oil phase, since it is the drug in the aqueous phase that can lead to irritation of the nasal mucosa.
2o By a hydroxylated oil we mean an oil that contains hydroxylated fatty acids. Preferred hydroxylated oils are hydroxylated vegetable oils, and a preferred hydroxylated vegetable oil for use in the present composition is castor oil.
2s Castor oil consists of the glycerides of ricinoleic acid which is a hydroxy fatty acid. By castor oil we include ricinus oil, oil of Palma Christie, tangantargon oil and Neoloid as described in the Merck Index 12th Edition p. 311. Castar oil is a fixed oil usually obtained by the cold pressing of the seeds of Ricinus Communis L., (Fam. Euphorbiaceae).
3o The fatty acid composition is stated in the Merck Index to be 87 s ricinoieic acid, 7 % oleic acid, 3 % linoleic acid, 2 % palmitic acid, 1 %
stearic acid and dihydroxystearic acid in trace amounts.
We also include the oil from Ricinus Zanzibarinus in our definition of s castor oil. This oil also has a high content of glycerides of ricinoleic acid (Evans, in Trease and Evans, Pharmacognosy, 13th Edition, Bailliere Tindall, London 1989, P. 333).
Conventional vegetable oils, such as soy bean oil, cotton seed oil and io arachis oil, used for the preparation of pharmaceutical emulsions do not demonstrate such good drug solubility. The advantages of castor oil could be due to the fact that it contains hydroxylated fatty acids.
The oil phase in the emulsion can constitute from 1 to 50% v/v of the ~5 emulsion. A preferred concentration of oil in the emulsion is from 10 to 40 % v/v and an especially preferred concentration is from 20 to 30 % v/v.
A wide variety of drugs, other than cannabinoids, can be included in the composition of the invention. Suitable drugs not only include analgesic 2o agents, such as NSAIDs, and drugs for the treatment of Parkinson's disease, but also drugs where rapid onset of action may be required, such as drugs for the treatment of nausea and vertigo, convulsions, panic attacks, cardiac problems, impotence, erectile dysfunction, migraine, sedation (particularly in children) and withdrawal symptoms. Suitable 2s drugs may also include benzodiazapines, midazolam, diazepam and diamorphine.
Suitable non-steroidal anti-inflammatory drugs (NSAIDs) inciude the cyclooxygenase (COX) COX-1 and COX-2 inhibitors. Specific 3o compounds which may be used in the compositions of the invention include ibuprofen, flurbiprofen, diclofenac, indomethacin, piroxicam, ketoprofen, etodolac, diflusinal, meloxicam, aceclofenac, fenoprofen, naproxen, tiaprofenic acid and tolmetin. Preferred compounds are ibuprofen and flurbiprofen.
s The loading of the drug in the emulsion will be determined by the dose of the drug required for a therapeutic effect and the solubility of the drug in the hydroxylated oil. Doses of 10 mg to 100 mg could be administered.
Some drugs may be oily in nature and thereby be miscible with the io hydroxylated oil.
Typically, the drug is comprised in the emulsion at a concentration of from 0.1 to 20 % w/v, preferably from 1 to 10% w/v, i.e. from 0.1 to 20, preferably from 1 to 10 g of drug in 100 ml of oil.
is The nasal administration of analgesics using the compositions of the invention may provide for direct access to sites of action such as the cerebrospinal fluid and the nervous ganglia associated with conditions such as migraine. Consequently, the required dose of a NSAID
2o administered nasally may be less than that required when given by the usual oral route.
In addition, the fact that some drugs will be mostly dissolved in the oil phase and, therefore, not in contact with water, may also help improve the 2s stability of the drug in the formulation.
The emulsion compositions of the invention can be prepared using conventional methods such as by homogenisation of a mixture of the oil and drug with an aqueous phase, optionally together with a stabilising agent. A microfluidiser or ultrasonic device can be used; the former is preferred for large scale production.
Where a stabiliser/emulsifier is used in the formation of the emulsion, it s should be one which confers good stability to the emulsion and is pharmaceutically acceptable.
One suitable stabiliser is a block copolymer containing a polyoxyethylene block, i.e. a block made up of repeating ethylene oxide moieties. A
suitable stabiliser of this type is Poloxamer, i.e. a polyoxyethylene-polyoxypropylene block copolymer, such as Poloxamer 188. See the Handbook of Pharmaceutical Excipients, p.352, 2nd Edn. Pharmaceutical Press, London, 1994, Eds, Wade and Welter.
~s A preferred stabiliser is a phospholipid emulsifier. Preferred phospholipids are the soy and egg lecithins, and egg lecithins, such as the material provided by Lipoid (Germany) known as Lipoid E80, which contains both phosphatidylcholine and phosphatidyl ethanoline, are particularly preferred. Other phospholipid materials could also be used 2o including phospholipid-polyethylene glycol (PEG) conjugates (PEGylated phospholipids) that have been described for use in liposome systems, e.g.
by Litzinger et al, Biochem Biophys Acta, 1190 (1994) 99-107.
The concentration of stabiliser/emulsifier can be from 0.1 to 10 % wlv in 2s the aqueous phase of the emulsion, i.e. from 0.1 to 10 g of stabiliser per 100 mls of the aqueous phase, but a preferred concentration is from 1 to % w/v.
The stability of the emulsion can be further enhanced by the addition of a 3o pharmaceutically acceptable co-emulsifier. Suitable co-emulsifiers include s the fatty acids and salts thereof and bile acid and salts thereof. Suitable fatty acids are those having greater than 8 carbon atoms in their structure with oleic acid being a preferred material. A preferred bile acid is deoxycholic acid. Suitable salts are the pharmaceutically acceptable salts s such as the alkali metal, e.g. Na and K, salts. These co-emulsifiers can be added at a concentration of 1 % w/v or less on the aqueous phase, i.e. lg or less of co-emulsifier per 100 mls of the aqueous phase of the emulsion.
Bile salts and oleic acid are preferred co-emulsifiers.
io The composition of the present invention may be adjusted, if necessary, to approximately the same osmotic pressure as that of the body fluids.
This may be desirable where the composition is to be applied to delicate tissue membranes, such as those found in the nasal cavity. For example, compositions comprising NSAIDs can exceed isotonicity, becoming is hypertonic. A composition which has been adjusted in this manner is said to be isotonic and will tend not to swell or contract the tissues with which it comes into contact and will result in minimal discomfort on application.
The formation of isotonic solutions can be achieved by adding an ionic compound to the composition such as sodium chloride, or by adding 2o glycerol.
It may also be appropriate to include buffering agents in the composition.
For example, a buffer may be needed to maintain a pH that is compatible with nasal fluid, to ensure emulsion stability or to ensure that the drug 2s does not partition from the emulsion oil phase into the aqueous phase.
It will be clear to the person skilled in the art that additional formulation components can be added to the emulsion. These could include agents that promote the transmucosal absorption of drugs such as surfactants, as so well as thickening agents and gelling agents that will serve to retain the formulation in the nasal cavity for an extended period of time. Suitable thickening and gelling agents include cellulose polymers, particularly sodium carboxymethyl cellulose, alginates, gellans, pectins, acrylic polymers, agar-agar, gum tragacanth, gum xanthan, hydroxyethyl s cellulose, chitosan, as well as block copolymers of the polyoxyethylene-polyoxypropylene class known as the poloxamers and poloxamines.
Preservative agents such as methyl parabenzoates, benzylalcohol and chlorobutanol could also be added.
~o The emulsion can be administered to the nasal cavity using conventional nasal spray devices. These devices can be single dose or multiple dose systems. Such devices can be obtained from companies such as Pfeiffer and Valois.
1s The present invention is now illustrated but not limited with reference to the following examples.
Example 1 Solubilit~of flurbiprofen in vegetable oils 2o The solubility of flurbiprofen in different vegetable oils was measured by the addition of increasing quantities of the drug to an oil system and determination of the maximum amount that will dissolve by observation of the resultant solution and the onset of a cloudy nature or precipitation.
The solubility of flurbiprofen (obtained from The Boots Co. Ltd.) at room 2s temperature measured in this way was less than 50 mg/ml in soybean oil BP (obtained from Kahlshams, Sweden) and 150 mg/ml in castor oil BP
(William Ransom, UK).
~o Example 2 s An oil in water emulsion containing 45 mg/ml flurbiprofen and a 30 % v/v oil phase was prepared as follows:
Approximately 60 ml of castor oil BP (William Ransom, UK) was warmed to 30-40°C and 11.25 g of flurbiprofen (Boots Co., UK) was 1o then added and the mixture stirred to dissolve. The volume of the flurbiprofen solution was adjusted to 75 ml by adding further castor oil.
Phosphate buffered saline (PBS) solution (pH 7.4) was prepared by dissolving a PBS tablet (Sigma, UK) in 200 ml of water. 150 ml of this 1s solution was warmed to 40°C and 3.0 g of egg yolk lecithin (Lipoid E80, Leopold, Germany) was added and mixed to disperse. To the egg yolk phospholipid dispersion was added 4.2 g of glycerol (Boots Co. Ltd.) to maintain isotonicity. This mixture was then added to the flurbiprofen/castor oil solution and the two phases mixed using a 2o Silverson L4R homogeniser, pulsed between speeds 5 and 10 for a period of 1 minute. This coarse emulsion was then passed three times through a Rannie Mini-Lab valve homogeniser at 10,000 psi to produce a milky off white emulsion. The emulsion had a fine particle size (about 200 nm as measured using the method of photon correlation spectroscopy) and was 2s stable on storage at room temperature. There was no evidence of separation of free oil nor drug crystals as viewed under a light microscope.
II
Example 3 irritation test in human In order to evaluate the relative irritancy of a solution and emulsion formulation of flurbiprofen two different formulations were evaluated.
Solution formulation: Flurbiprofen as the potassium salt was dissolved in water at a concentration of 45 mg/ml and the resulting solution administered to the nose using a Pfeiffer multidose nasal device.
A volume of 50 ~1 was administered into one nostril.
to Emulsion formulation: An oil-in-water emulsion formulation as described in example 2 containing 45 mg/ml of flurbiprofen was prepared and filled into a Pfeiffer multidose nasal spray device. A dose of 50 ~1 was administered into one nostril.
~s One subject (female, age 50) tested each formulation on two separate occasions.
Irritancy was assessed using an analogue scale. The solution formulation 2o based on the potassium salt of flurbiprofen was noted as being irritant at a value of 10 on the irritancy scale.
The emulsion formulation was less irritant, being assessed as 4 on the irritancy scale.
Example 4 Solubility of non-steroidal drubs in castor oil and soybean oil The solubility of additional NSAIDs in castor oil and soybean oil was so measured at room temperature as in Example 1. Ibuprofen, indomethacin and naproxen (as obtained from Sigma Chemical Co.) were investigated.
The results in Table 1 demonstrate the beneficial effect of a hydroxylated vegetable oil (namely castor oil) in improving drug solubility so that a nasal emulsion of low irritation can be formulated.
s Table 1 The solubility of ibuprofen, indomethacin and naproxen in castor oil (B.P) and soybean oil Drug Solubility in castorSolubility in soybean oil oil (mg~g) (mg~g) Ibuprofen > 100 > 30 < 40 Indomethacin> 15 < 20 < 5 Naproxen > 20 < 40 < 10 Apomorphine > 30 < 50 < 10 SUBSTITUTE SHEET (RULE 26)
The present invention relates generally to a new composition for delivery of drugs to the nose far systemic absorption. More specifically, the s present invention relates to an oil-in-water emulsion formulation for the delivery of poorly water soluble drugs, which need to be given in relatively high doses, to the nose for systemic absorption.
Examples of poorly water soluble drugs that are given in relatively high io doses are analgesics, including aon-steroidal anti-inflammatory drugs (NSAIDs), and anti-Parkinson drugs. By a relatively high dose of drug, we mean more than 1 mg of drug.
The nasal route of drug delivery affords rapid absorption of drugs into the is blood circulation. In some cases the absorption of almost the whole dose can be achieved and the pharmacokinetics can be similar to intravenous administration. Such rapid and effective drug delivery can be useful in the treatment of crisis situations such as pain (to include breakthrough pain, headache), migraine, convulsions, impotence and nausea. Nasal 2o formulations for the delivery of analgesic agents such as morphine, butorphanol, fentanyl, buprenorphine have been described. For a review, see Nasal Systemic Delivery, Eds. Chien et al. Dekker, New York, 2s The non-steroidal anti-inflammatory drugs (NSAIDs) such as the cyclooxygenase (COX) COX-1 and COX-2 inhibitors have an important role in pain management. Compounds include ibuprofen, flurbiprofen, diclofenac, indomethacin, piroxicam, ketoprofen, etodolac, diflusinal, meloxicam, aceclofenac, fenoprofen, naproxen, tiaprofenic acid and 3o tolmetin. Such drugs are normally given by mouth for absorption from i the gastrointestinal tract, but can also be given by other routes, which include injection.
Nasal delivery of poorly water soluble drugs that need to be given in a s relatively high dose is often problematic. The maximum volume to be given in each nostril is 100 to 125 ~.1 and with a low solubility of the drug, it is normally not possible to achieve a simple solution formulation.
Moreover, the compounds can be irritant to mucosae.
io It is known that solutions of non-steroidal anti-inflammatory drugs at relatively high concentrations can be prepared by the use of certain salt forms, e.g. K+, or by adjustment of pH. However, the osmolarity of such solutions can readily exceed isotonicity and, as a consequence, the solutions can be irritant.
~s WO-97/03659 describes the use of non-steroidal anti-inflammatory drugs (e.g. diclofenac or ibuprofen) for the treatment of nasal polyps, chronic rhinosinusitis or anosmia. There is no suggestion that the nasal route can be used for the systemic delivery of NSAIDs, nor is there a description of 2o a two phase system, such as an emulsion, for this purpose.
EP-A-0524,587 describes the nasal administration of Ketoroiac (US-4,0$9,969) for analgesic and anti-inflammatory activity. Formulations based on the concepts of bioadhesion, e.g. using cellulose gums and block 2s copolymers, as well as formulations containing enhancing agents are described. The use of an emulsion formulation was not described.
US-5,707,644 describes the nasal delivery of NSAIDs and analgesics to the systemic circulation using small bioadhesive microspheres. There is no suggestion that a two phase liquid formulation, such as an emulsion, could be used.
Oil-in-water emulsion systems for the improved delivery of drugs via the s nasal route have been described previously. Ko et al. (J. Microencaps.
15, 197, 1998) administered testosterone to rabbits. The drug was dissolved in soybean oil. Karali et al. (Pharm. Res. 9, 1024, 1992) used an oleic acid mono-olefin emulsion to deliver a lipid soluble resin inhibitor. The emulsion was effective because it contained membrane io modifying adjuvants. The use of a hydroxylated oil such as castor oil was not disclosed.
WO-93/12764 and GB-2,133,691 describe the potential use of emulsion systems for the nasal delivery of nicotine. The teaching of these two ~s patents is to use systems of a defined viscosity and an oily emulsion is mentioned simply as a formulation option.
JP-4-173736 describes amphotericin containing emulsions and lyophilised counterparts based on soybean oil as the oily phase for use as nasal drops.
2o It is well known that in such emulsions the drug is intercalated into the surface layer of the emulsion and is not dissolved in the oily phase (Davis et al. Ann N.Y. Acad. Sci. 507, 75, 1987).
JP-5-124965 describes the local treatment of nasal disorders using drugs 2s dissolved in the oily phase of an emulsion. The oil phase was soybean oil and the drugs were steroid and steroid derivatives.
JP-7-258069 describes sustained release nasal drops containing vasoconstrictor and antihistamines in an oil-in-water emulsion for local 30 effect.
Emulsion vehicles have also been used to improve the nasal delivery of polar drugs such as peptides and as vaccine adjuvants. In such formulations, the drug is not dissolved in the oil phase of the emulsion, but can be adsorbed to the surface of the emulsion droplets (WO-s 95/11700, US-5,514,670, WO-93/05805, US-5,716,637).
US-5,179,079 describes the use of emulsions to disperse absorption promoting agents such as phospholipids.
io In none of these prior art documents have oil-in-water emulsions based on hydroxylated oils, such as castor oil, been used for the nasal administration of drugs in order to provide for solubilisation of the therapeutic agent and reduced nasal irritation.
is The present applicant has developed an oil-in-water formulation that can provide for the effective nasal delivery of drugs which are poorly soluble in water, such as analgesics, including NSAIDs, and drugs for the treatment of Parkinson's disease and impotence. The composition may also demonstrate a reduced nasal irritation.
According to the present invention, there is provided a pharmaceutical composition comprising (i) an oil-in-water emulsion and (ii) a drug other than a cannabinoid dissolved in the emulsion, wherein the oil phase comprises a hydroxylated oil, particularly a hydroxylated vegetable oil.
The composition of the invention can provide for the delivery of poorly water soluble drugs, which are given in a relatively high dose, to the nasal mucosa for subsequent delivery to the systemic circulation. By a poorly water soluble drug we mean a drug with a solubility in water less than 10 mg/ml at pH 7.4 at 25°C. By _a relatively high dose of drug we mean more than 1 mg of drug.
The drug, which in a preferred embodiment is a poorly water soluble s drug, is preferably largely contained within the oil phase of the oil-in-water emulsion. By "largely" we mean that more than one half, i.e.
more than SO % , and preferably more than 75 % of the available drug is dissolved in the oil phase on a weight basis.
io The hydroxylated oil which is contained in the composition of the invention provides for solubilisation of the drug and can provide for effective solubilisation of poorly water soluble drugs so that a therapeutically relevant dose can be delivered via the nose. Moreover, the emulsion formulation can greatly reduce any irritation associated with the is drug. Without wishing to be bound by any theory, it is believed that such reduction in irritation is due to the fact that the drug is dissolved largely in the oil phase, since it is the drug in the aqueous phase that can lead to irritation of the nasal mucosa.
2o By a hydroxylated oil we mean an oil that contains hydroxylated fatty acids. Preferred hydroxylated oils are hydroxylated vegetable oils, and a preferred hydroxylated vegetable oil for use in the present composition is castor oil.
2s Castor oil consists of the glycerides of ricinoleic acid which is a hydroxy fatty acid. By castor oil we include ricinus oil, oil of Palma Christie, tangantargon oil and Neoloid as described in the Merck Index 12th Edition p. 311. Castar oil is a fixed oil usually obtained by the cold pressing of the seeds of Ricinus Communis L., (Fam. Euphorbiaceae).
3o The fatty acid composition is stated in the Merck Index to be 87 s ricinoieic acid, 7 % oleic acid, 3 % linoleic acid, 2 % palmitic acid, 1 %
stearic acid and dihydroxystearic acid in trace amounts.
We also include the oil from Ricinus Zanzibarinus in our definition of s castor oil. This oil also has a high content of glycerides of ricinoleic acid (Evans, in Trease and Evans, Pharmacognosy, 13th Edition, Bailliere Tindall, London 1989, P. 333).
Conventional vegetable oils, such as soy bean oil, cotton seed oil and io arachis oil, used for the preparation of pharmaceutical emulsions do not demonstrate such good drug solubility. The advantages of castor oil could be due to the fact that it contains hydroxylated fatty acids.
The oil phase in the emulsion can constitute from 1 to 50% v/v of the ~5 emulsion. A preferred concentration of oil in the emulsion is from 10 to 40 % v/v and an especially preferred concentration is from 20 to 30 % v/v.
A wide variety of drugs, other than cannabinoids, can be included in the composition of the invention. Suitable drugs not only include analgesic 2o agents, such as NSAIDs, and drugs for the treatment of Parkinson's disease, but also drugs where rapid onset of action may be required, such as drugs for the treatment of nausea and vertigo, convulsions, panic attacks, cardiac problems, impotence, erectile dysfunction, migraine, sedation (particularly in children) and withdrawal symptoms. Suitable 2s drugs may also include benzodiazapines, midazolam, diazepam and diamorphine.
Suitable non-steroidal anti-inflammatory drugs (NSAIDs) inciude the cyclooxygenase (COX) COX-1 and COX-2 inhibitors. Specific 3o compounds which may be used in the compositions of the invention include ibuprofen, flurbiprofen, diclofenac, indomethacin, piroxicam, ketoprofen, etodolac, diflusinal, meloxicam, aceclofenac, fenoprofen, naproxen, tiaprofenic acid and tolmetin. Preferred compounds are ibuprofen and flurbiprofen.
s The loading of the drug in the emulsion will be determined by the dose of the drug required for a therapeutic effect and the solubility of the drug in the hydroxylated oil. Doses of 10 mg to 100 mg could be administered.
Some drugs may be oily in nature and thereby be miscible with the io hydroxylated oil.
Typically, the drug is comprised in the emulsion at a concentration of from 0.1 to 20 % w/v, preferably from 1 to 10% w/v, i.e. from 0.1 to 20, preferably from 1 to 10 g of drug in 100 ml of oil.
is The nasal administration of analgesics using the compositions of the invention may provide for direct access to sites of action such as the cerebrospinal fluid and the nervous ganglia associated with conditions such as migraine. Consequently, the required dose of a NSAID
2o administered nasally may be less than that required when given by the usual oral route.
In addition, the fact that some drugs will be mostly dissolved in the oil phase and, therefore, not in contact with water, may also help improve the 2s stability of the drug in the formulation.
The emulsion compositions of the invention can be prepared using conventional methods such as by homogenisation of a mixture of the oil and drug with an aqueous phase, optionally together with a stabilising agent. A microfluidiser or ultrasonic device can be used; the former is preferred for large scale production.
Where a stabiliser/emulsifier is used in the formation of the emulsion, it s should be one which confers good stability to the emulsion and is pharmaceutically acceptable.
One suitable stabiliser is a block copolymer containing a polyoxyethylene block, i.e. a block made up of repeating ethylene oxide moieties. A
suitable stabiliser of this type is Poloxamer, i.e. a polyoxyethylene-polyoxypropylene block copolymer, such as Poloxamer 188. See the Handbook of Pharmaceutical Excipients, p.352, 2nd Edn. Pharmaceutical Press, London, 1994, Eds, Wade and Welter.
~s A preferred stabiliser is a phospholipid emulsifier. Preferred phospholipids are the soy and egg lecithins, and egg lecithins, such as the material provided by Lipoid (Germany) known as Lipoid E80, which contains both phosphatidylcholine and phosphatidyl ethanoline, are particularly preferred. Other phospholipid materials could also be used 2o including phospholipid-polyethylene glycol (PEG) conjugates (PEGylated phospholipids) that have been described for use in liposome systems, e.g.
by Litzinger et al, Biochem Biophys Acta, 1190 (1994) 99-107.
The concentration of stabiliser/emulsifier can be from 0.1 to 10 % wlv in 2s the aqueous phase of the emulsion, i.e. from 0.1 to 10 g of stabiliser per 100 mls of the aqueous phase, but a preferred concentration is from 1 to % w/v.
The stability of the emulsion can be further enhanced by the addition of a 3o pharmaceutically acceptable co-emulsifier. Suitable co-emulsifiers include s the fatty acids and salts thereof and bile acid and salts thereof. Suitable fatty acids are those having greater than 8 carbon atoms in their structure with oleic acid being a preferred material. A preferred bile acid is deoxycholic acid. Suitable salts are the pharmaceutically acceptable salts s such as the alkali metal, e.g. Na and K, salts. These co-emulsifiers can be added at a concentration of 1 % w/v or less on the aqueous phase, i.e. lg or less of co-emulsifier per 100 mls of the aqueous phase of the emulsion.
Bile salts and oleic acid are preferred co-emulsifiers.
io The composition of the present invention may be adjusted, if necessary, to approximately the same osmotic pressure as that of the body fluids.
This may be desirable where the composition is to be applied to delicate tissue membranes, such as those found in the nasal cavity. For example, compositions comprising NSAIDs can exceed isotonicity, becoming is hypertonic. A composition which has been adjusted in this manner is said to be isotonic and will tend not to swell or contract the tissues with which it comes into contact and will result in minimal discomfort on application.
The formation of isotonic solutions can be achieved by adding an ionic compound to the composition such as sodium chloride, or by adding 2o glycerol.
It may also be appropriate to include buffering agents in the composition.
For example, a buffer may be needed to maintain a pH that is compatible with nasal fluid, to ensure emulsion stability or to ensure that the drug 2s does not partition from the emulsion oil phase into the aqueous phase.
It will be clear to the person skilled in the art that additional formulation components can be added to the emulsion. These could include agents that promote the transmucosal absorption of drugs such as surfactants, as so well as thickening agents and gelling agents that will serve to retain the formulation in the nasal cavity for an extended period of time. Suitable thickening and gelling agents include cellulose polymers, particularly sodium carboxymethyl cellulose, alginates, gellans, pectins, acrylic polymers, agar-agar, gum tragacanth, gum xanthan, hydroxyethyl s cellulose, chitosan, as well as block copolymers of the polyoxyethylene-polyoxypropylene class known as the poloxamers and poloxamines.
Preservative agents such as methyl parabenzoates, benzylalcohol and chlorobutanol could also be added.
~o The emulsion can be administered to the nasal cavity using conventional nasal spray devices. These devices can be single dose or multiple dose systems. Such devices can be obtained from companies such as Pfeiffer and Valois.
1s The present invention is now illustrated but not limited with reference to the following examples.
Example 1 Solubilit~of flurbiprofen in vegetable oils 2o The solubility of flurbiprofen in different vegetable oils was measured by the addition of increasing quantities of the drug to an oil system and determination of the maximum amount that will dissolve by observation of the resultant solution and the onset of a cloudy nature or precipitation.
The solubility of flurbiprofen (obtained from The Boots Co. Ltd.) at room 2s temperature measured in this way was less than 50 mg/ml in soybean oil BP (obtained from Kahlshams, Sweden) and 150 mg/ml in castor oil BP
(William Ransom, UK).
~o Example 2 s An oil in water emulsion containing 45 mg/ml flurbiprofen and a 30 % v/v oil phase was prepared as follows:
Approximately 60 ml of castor oil BP (William Ransom, UK) was warmed to 30-40°C and 11.25 g of flurbiprofen (Boots Co., UK) was 1o then added and the mixture stirred to dissolve. The volume of the flurbiprofen solution was adjusted to 75 ml by adding further castor oil.
Phosphate buffered saline (PBS) solution (pH 7.4) was prepared by dissolving a PBS tablet (Sigma, UK) in 200 ml of water. 150 ml of this 1s solution was warmed to 40°C and 3.0 g of egg yolk lecithin (Lipoid E80, Leopold, Germany) was added and mixed to disperse. To the egg yolk phospholipid dispersion was added 4.2 g of glycerol (Boots Co. Ltd.) to maintain isotonicity. This mixture was then added to the flurbiprofen/castor oil solution and the two phases mixed using a 2o Silverson L4R homogeniser, pulsed between speeds 5 and 10 for a period of 1 minute. This coarse emulsion was then passed three times through a Rannie Mini-Lab valve homogeniser at 10,000 psi to produce a milky off white emulsion. The emulsion had a fine particle size (about 200 nm as measured using the method of photon correlation spectroscopy) and was 2s stable on storage at room temperature. There was no evidence of separation of free oil nor drug crystals as viewed under a light microscope.
II
Example 3 irritation test in human In order to evaluate the relative irritancy of a solution and emulsion formulation of flurbiprofen two different formulations were evaluated.
Solution formulation: Flurbiprofen as the potassium salt was dissolved in water at a concentration of 45 mg/ml and the resulting solution administered to the nose using a Pfeiffer multidose nasal device.
A volume of 50 ~1 was administered into one nostril.
to Emulsion formulation: An oil-in-water emulsion formulation as described in example 2 containing 45 mg/ml of flurbiprofen was prepared and filled into a Pfeiffer multidose nasal spray device. A dose of 50 ~1 was administered into one nostril.
~s One subject (female, age 50) tested each formulation on two separate occasions.
Irritancy was assessed using an analogue scale. The solution formulation 2o based on the potassium salt of flurbiprofen was noted as being irritant at a value of 10 on the irritancy scale.
The emulsion formulation was less irritant, being assessed as 4 on the irritancy scale.
Example 4 Solubility of non-steroidal drubs in castor oil and soybean oil The solubility of additional NSAIDs in castor oil and soybean oil was so measured at room temperature as in Example 1. Ibuprofen, indomethacin and naproxen (as obtained from Sigma Chemical Co.) were investigated.
The results in Table 1 demonstrate the beneficial effect of a hydroxylated vegetable oil (namely castor oil) in improving drug solubility so that a nasal emulsion of low irritation can be formulated.
s Table 1 The solubility of ibuprofen, indomethacin and naproxen in castor oil (B.P) and soybean oil Drug Solubility in castorSolubility in soybean oil oil (mg~g) (mg~g) Ibuprofen > 100 > 30 < 40 Indomethacin> 15 < 20 < 5 Naproxen > 20 < 40 < 10 Apomorphine > 30 < 50 < 10 SUBSTITUTE SHEET (RULE 26)
Claims (14)
1. A pharmaceutical composition adapted for nasal administration comprising (i) an oil-in-water emulsion and (ii) a drug dissolved in the emulsion, wherein the oil phase comprises a hydroxylated oil and wherein the drug is for systemic delivery and is also an analgesic agent, a drug for the treatment of Parkinson's disease, a drug for the treatment of impotence or a non-steroidal anti-inflammatory drug (NSAID), other than a cannabinoid.
2. A composition adapted for nasal administration comprising (i) an oil-in-water emulsion and (ii) a drug dissolved in the emulsion, wherein the oil phase comprises a hydroxylated oil and wherein the drug is for systemic delivery and is also an analgesic agent, a drug for the treatment of Parkinson's disease, a drug for the treatment of impotence or a non-steroidal anti-inflammatory drug (NSAID), other than a cannabinoid, for use in medicine.
3. A composition according to Claim 1 or Claim 2, wherein the hydroxylated oil is a hydroxylated vegetable oil.
4. A composition according to Claim 3, wherein the hydroxylated vegetable oil is castor oil.
5. A composition according to any one of Claims 1 to 4, wherein the NSAID is flurbiprofen.
6. A composition according to any one of Claims 1 to 4, wherein the NSAID is ibuprofen.
7. A composition according to any one of Claims 1 to 4, wherein the NSAID is a COX-1 or COX-2 inhibitor.
8. A composition according to any one of Claims 1 to 7, wherein more than 50 % of the drug is dissolved in the oil phase on a weight basis.
9. A composition according to Claim 8, wherein more than 75 % of the drug is dissolved in the oil phase on a weight basis.
10. A method for the treatment of pain which comprises delivering an oil-in-water emulsion containing a systemically active drug other than a cannabinoid by the nasal route.
11. A method according to Claim 10, wherein the drug is a NSAID.
12. The use of a composition according to any one of Claims 1 to 9 for the systemic delivery of a drug by the nasal route.
13. The use of a composition according to any one of Claims 1 to 9 in the manufacture of a medicament for nasal administration.
14. The use of a composition according to any one of Claims 1 to 9 in the manufacture of a medicament for systemic delivery of the drug by the nasal route.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9823246.5 | 1998-10-24 | ||
| GBGB9823246.5A GB9823246D0 (en) | 1998-10-24 | 1998-10-24 | A nasal drug delivery composition |
| PCT/GB1999/003489 WO2000024373A1 (en) | 1998-10-24 | 1999-10-21 | O/w emulsion comprising an hydroxylated oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2347032A1 true CA2347032A1 (en) | 2000-05-04 |
Family
ID=10841182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002347032A Abandoned CA2347032A1 (en) | 1998-10-24 | 1999-10-21 | O/w emulsion comprising an hydroxylated oil |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20010055569A1 (en) |
| EP (1) | EP1123085A1 (en) |
| JP (1) | JP2003519085A (en) |
| AU (1) | AU765251B2 (en) |
| CA (1) | CA2347032A1 (en) |
| GB (1) | GB9823246D0 (en) |
| NO (1) | NO20011985L (en) |
| NZ (1) | NZ510886A (en) |
| WO (1) | WO2000024373A1 (en) |
| ZA (1) | ZA200102690B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10736842B2 (en) | 2014-06-25 | 2020-08-11 | Synergia Bio Sciences Private Limited | Pharmaceutical oil-in-water nano-emulsion |
| US11400048B2 (en) | 2014-06-25 | 2022-08-02 | Synergia Bio Sciences Private Limited | Pharmaceutical oil-in-water nano-emulsion |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022683B1 (en) | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
| US20020035107A1 (en) | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
| CA2417727C (en) | 2000-07-31 | 2009-09-01 | Nycomed Danmark A/S | Fentanyl composition for nasal administration |
| GB0116107D0 (en) * | 2001-06-30 | 2001-08-22 | West Pharm Serv Drug Res Ltd | Pharmaceutical composition |
| DE10161077A1 (en) | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Highly concentrated stable meloxicam solutions for needleless injection |
| US20050220888A1 (en) * | 2002-01-31 | 2005-10-06 | Lakahmi Putcha | Controlled release compositions and methods for using same |
| US20030225044A1 (en) * | 2002-06-03 | 2003-12-04 | Bachman Stephen E. | Method to increase serum levels of vitamins in animals including humans |
| US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
| ATE319426T1 (en) * | 2003-11-11 | 2006-03-15 | Mattern Udo | NASAL FORMULATION WITH CONTROLLED RELEASE OF SEXUAL HORMONES |
| ATE474591T1 (en) | 2003-12-08 | 2010-08-15 | Cpex Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR INSULIN TREATMENT |
| EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
| AU2005329255B2 (en) | 2004-04-15 | 2010-09-30 | Chiasma, Inc. | Compositions capable of facilitating penetration across a biological barrier |
| DE102004021281A1 (en) * | 2004-04-29 | 2005-11-24 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam formulations in veterinary medicine |
| US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
| JP2009510007A (en) * | 2005-09-30 | 2009-03-12 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pharmaceutical preparation containing meloxicam |
| US20070104741A1 (en) * | 2005-11-07 | 2007-05-10 | Murty Pharmaceuticals, Inc. | Delivery of tetrahydrocannabinol |
| WO2008020318A2 (en) * | 2006-03-30 | 2008-02-21 | Engene, Inc. | Non-viral compositions and methods for transfecting gut cells in vivo |
| GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
| CA2664427C (en) | 2006-10-04 | 2012-06-05 | M & P Patent Aktiengesellschaft | Controlled release delivery system for nasal application of neurotransmitters |
| JP5623406B2 (en) | 2008-09-17 | 2014-11-12 | キアズマ インコーポレイテッド | Pharmaceutical compositions and related delivery methods |
| AU2010347598B2 (en) | 2010-03-03 | 2014-11-27 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| AR086400A1 (en) | 2011-05-13 | 2013-12-11 | Trimel Pharmaceuticals Corp | FORMULATIONS IN INTRANASAL GEL OF TESTOSTERONE IN DOSE OF LOWER POWER AND USE OF THE SAME FOR THE TREATMENT OF ANORGASMIA OR THE DISORDER OF HYPOACTIVE SEXUAL DESIRE |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| AU2016215350B2 (en) | 2015-02-03 | 2021-11-25 | Amryt Endo, Inc. | Method of treating diseases |
| AR102172A1 (en) * | 2015-10-05 | 2017-02-08 | Química Luar S R L | A BACTERICIDE AND VIRUCIDE PHARMACEUTICAL COMPOSITION |
| MX2020003697A (en) * | 2017-10-20 | 2020-08-13 | Chiesi Farm Spa | Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof. |
| MX2021004238A (en) * | 2018-10-15 | 2021-05-27 | M A Med Alliance Sa | Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs. |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693337A (en) * | 1994-07-13 | 1997-12-02 | Wakamoto Pharmaceutical Co., Ltd. | Stable lipid emulsion |
| ES2094688B1 (en) * | 1994-08-08 | 1997-08-01 | Cusi Lab | MANOEMULSION OF THE TYPE OF OIL IN WATER, USEFUL AS AN OPHTHALMIC VEHICLE AND PROCEDURE FOR ITS PREPARATION. |
| SE9403389D0 (en) * | 1994-10-06 | 1994-10-06 | Astra Ab | Pharmaceutical composition containing derivatives of sex hormones |
| EP0760237A1 (en) * | 1995-08-30 | 1997-03-05 | Cipla Limited | Oil-in-water microemulsions |
-
1998
- 1998-10-24 GB GBGB9823246.5A patent/GB9823246D0/en not_active Ceased
-
1999
- 1999-10-21 AU AU63536/99A patent/AU765251B2/en not_active Ceased
- 1999-10-21 CA CA002347032A patent/CA2347032A1/en not_active Abandoned
- 1999-10-21 WO PCT/GB1999/003489 patent/WO2000024373A1/en not_active Application Discontinuation
- 1999-10-21 EP EP99950947A patent/EP1123085A1/en not_active Withdrawn
- 1999-10-21 NZ NZ510886A patent/NZ510886A/en unknown
- 1999-10-21 JP JP2000577984A patent/JP2003519085A/en active Pending
-
2001
- 2001-04-02 ZA ZA200102690A patent/ZA200102690B/en unknown
- 2001-04-23 NO NO20011985A patent/NO20011985L/en not_active Application Discontinuation
- 2001-04-24 US US09/841,228 patent/US20010055569A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10736842B2 (en) | 2014-06-25 | 2020-08-11 | Synergia Bio Sciences Private Limited | Pharmaceutical oil-in-water nano-emulsion |
| US11400048B2 (en) | 2014-06-25 | 2022-08-02 | Synergia Bio Sciences Private Limited | Pharmaceutical oil-in-water nano-emulsion |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ510886A (en) | 2004-09-24 |
| AU6353699A (en) | 2000-05-15 |
| EP1123085A1 (en) | 2001-08-16 |
| WO2000024373A1 (en) | 2000-05-04 |
| NO20011985D0 (en) | 2001-04-23 |
| JP2003519085A (en) | 2003-06-17 |
| AU765251B2 (en) | 2003-09-11 |
| US20010055569A1 (en) | 2001-12-27 |
| NO20011985L (en) | 2001-04-23 |
| GB9823246D0 (en) | 1998-12-16 |
| ZA200102690B (en) | 2003-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU765251B2 (en) | O/W emulsion comprising an hydroxylated oil | |
| ES2325364T3 (en) | ANALGESICS. | |
| Vandamme | Microemulsions as ocular drug delivery systems: recent developments and future challenges | |
| JP5792299B2 (en) | 6′-Fluoro- (N-methyl- or N, N-dimethyl-)-4-phenyl-4 ′, 9′-dihydro-3′H-spiro [cyclohexane-1, for the treatment of neuropathic pain Pharmaceutical dosage forms comprising 1'-pyrano [3,4, b] indole] -4-amine | |
| US8133502B2 (en) | System for delivering a composition to the nasal membrane and method of using same | |
| JP4549006B2 (en) | Gel ointment | |
| JP2001509136A (en) | Treatment of equine laminitis | |
| JP5052558B2 (en) | Gel ointment | |
| PT2068825E (en) | Controlled release delivery system for nasal application of neurotransmitters | |
| RU2560677C2 (en) | Skin composition, including vitamin d analogue and mixture of solvent and surface-active substances | |
| TWI723032B (en) | Diacerein or rhein topical formulations and uses thereof | |
| US9084818B2 (en) | Topical dermal delivery compositions using self assembling nanoparticles with cetylated components | |
| US20220151952A1 (en) | Novel Nano-Formulation of Cannabidiol (CBD) and Other Cannabinoids for Treatment of Skin Diseases | |
| Lee et al. | Microemulsion-based hydrogel formulation of itraconazole for topical delivery | |
| BR112012015449B1 (en) | CALCIPOTRIOL MONOHYDRATE SUSPENSION, AND PROCESS TO PREPARE CALCIPOTRIOL MONOHYDRATE NANOCRYSTALS | |
| Ali | Formulation Development And Evaluation Of Niosomal Gel Containing Antiarthritic Drugs | |
| Raj et al. | Journal of Comprehensive Pharmacy | |
| KR19990047898A (en) | Analgesic anti-inflammatory gels containing diclofenac salt as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |